A number of other brokerages have also recently issued reports on FSNUY. Deutsche Bank Aktiengesellschaft restated a “hold” rating on shares of Fresenius SE & Co. KGaA in a report on Wednesday. Zacks Investment Research cut shares of Fresenius SE & Co. KGaA from a “buy” rating to a “hold” rating in a report on Tuesday, April 27th. Barclays reiterated an “overweight” rating on shares of Fresenius SE & Co. KGaA in a report on Wednesday, April 28th. DZ Bank reiterated a “buy” rating on shares of Fresenius SE & Co. KGaA in a report on Wednesday, May 12th. Finally, Morgan Stanley reiterated an “overweight” rating on shares of Fresenius SE & Co. KGaA in a report on Wednesday. One research analyst has rated the stock with a sell rating, four have assigned a hold rating and six have issued a buy rating to the company. Fresenius SE & Co. KGaA has an average rating of “Hold” and a consensus target price of $13.00.
Shares of OTCMKTS FSNUY traded up $0.28 during trading on Thursday, reaching $13.27. The company had a trading volume of 8,435 shares, compared to its average volume of 11,528. Fresenius SE & Co. KGaA has a 52 week low of $9.17 and a 52 week high of $14.81. The stock has a market cap of $29.53 billion, a PE ratio of 15.08 and a beta of 1.37. The company has a current ratio of 1.05, a quick ratio of 0.79 and a debt-to-equity ratio of 0.54. The business’s 50 day moving average is $13.49.
About Fresenius SE & Co. KGaA
Fresenius SE & Co KGaA, a health care group, provides products and services for dialysis, hospitals, and outpatient medical care Germany and internationally. The company operates through four segments: Fresenius Medical Care, Fresenius Kabi, Fresenius Helios, and Fresenius Vamed. The Fresenius Medical Care segment offers products and services for patients with chronic kidney failure.
Featured Story: Cryptocurrencies
Receive News & Ratings for Fresenius SE & Co. KGaA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fresenius SE & Co. KGaA and related companies with MarketBeat.com's FREE daily email newsletter.